

Amendments to the Claims:

This listing of claims will replace all prior versions, and listings of claims in the application:

Listing of Claims:

1. (original): A method for preventing an infection in a mammal, said method comprising: administering a pharmaceutically effective amount of a liposomal formulation to said mammal, wherein said liposomal formulation comprises:
 - a) a lipid vesicle; and
 - b) at least one single chain lipid active agent.
2. (original): The method of claim 1, wherein said active agent comprises an aliphatic hydrocarbon moiety.
3. (original): The method of claim 1, wherein said active agent is selected from the group consisting of a monoglyceride, a fatty acid, a lysophospholipid, and a combination thereof.
4. (original): The method of claim 1, wherein said infection is a viral infection.
5. (original): The method of claim 4, wherein said virus is an enveloped virus.
6. (original): The method of claim 5, wherein said virus is selected from the group consisting of VSV, VV, MV, HSV, and HIV.
7. (original): The method of claim 1, wherein said infection is a bacterial infection.
8. (original): The method of claim 7, wherein said bacterial infection is selected from the group consisting of Gonorrhea and Chlamydia.

9. (original): The method of claim 1, wherein said infection is a parasitic protozoan infection.

10. (original): The method of claim 7, wherein said protozoa is *Giardia lamblia*.

11. (original): The method of claim 1, wherein said formulation is selected from the group consisting of a topical formulation, an oral formulation, a mucosal formulation, a nasal formulation, an ophthalmic formulation, a rectal formulation, vaginal formulation, parenteral formulation and dermal formulation.

12. (withdrawn): A liposomal formulation comprising:
- a) a lipid vesicle; and
 - b) at least one single chain lipid active agent.

13. (withdrawn): The liposomal formulation of claim 12, wherein said active agent is selected from the group consisting of a monoglyceride, a fatty acid, a lysophospholipid, and a combination thereof.

14. (withdrawn): The liposomal formulation of claim 13, wherein said active agent is a monoglyceride.

15. (withdrawn): The liposomal formulation of claim 14, wherein said monoglyceride is a monoalkyletherglyceride with a number of carbon atoms in the alkyl moiety portion being from about 2 to about 18.

16. (withdrawn): The liposomal formulation of claim 15, wherein said monoglyceride is selected from the group consisting of 1 O-alkyl-sn-glycerol, 2-O-alkyl-sn-glycerol, and a mixture thereof.

17. (withdrawn): The liposomal formulation of claim 16, wherein said monoglyceride is 1-O-octyl-sn-glycerol, 2-O-octyl-sn-glycerol, and a mixture thereof.

18. (withdrawn): The liposomal formulation of claim **14**, wherein said monoglyceride is a single chain fatty acid monoglycerides with a number of carbon atoms in the fatty acid moiety portion being from about 6 and about 12.

19. (withdrawn): The liposomal formulation of claim **12**, wherein said lipid vesicle comprises a phospholipid.

20. (withdrawn): The liposomal formulation of claim **19**, wherein said phospholipid is phosphatidylcholine.

21. (withdrawn): The liposomal formulation of claim **20**, wherein said lipid vesicle further comprises a diluent selected from the group consisting of a co-solvent, a buffer solution, an anti-oxidant, a preservative, a thickening agent and a mixture thereof.

22. (withdrawn): The liposomal formulation of claim **21**, wherein said co-solvent comprises propylene glycol, ethanol, water or mixtures thereof.

23. (withdrawn): The liposomal formulation of claim **21**, wherein said anti-oxidant comprises vitamin E acetate.

24. (withdrawn): The liposomal formulation of claim **21**, wherein said preservative comprises methylparaben, propylparaben or mixtures thereof.

25. (withdrawn): The liposomal formulation of claim **21**, wherein said thickening agent comprises Carbopol, Crothix or mixtures thereof.

26. (withdrawn): The liposomal formulation of claim **12**, wherein said lipid vesicle is unilamellar.

27. (withdrawn): The liposomal formulation of claim **12**, wherein said lipid vesicle is multilamellar.

28. (withdrawn): The liposomal formulation of claim **12**, wherein said lipid vesicle is oligolamellar.

29. (withdrawn): The liposomal formulation of claim **12**, wherein said lipid vesicle comprises a co-lipid.

30. (withdrawn): The liposomal formulation of claim **29**, wherein said co-lipid is selected from the group consisting of a cholesterol, a phospholipid, a cationic lipid, an anionic lipid, and a combination thereof.

31. (withdrawn): The liposomal formulation of claim **30**, wherein said cationic lipid is selected from the group consisting of stearyl-amine, DC-Chol, DOTAP, and a combination thereof.

32. (withdrawn): The liposomal formulation of claim **30**, wherein said anionic lipid is selected from the group consisting of PS, PG, and a combination thereof.

33. (withdrawn): The liposomal formulation of claim **12**, wherein said formulation is a topical formulation.

34. (withdrawn): The liposomal formulation of claim **33**, wherein said topical formulation is selected from the group consisting of cream, a gel, a lotion, a suppository, a fluid suspension, and a paste.

35. (withdrawn): The liposomal formulation of claim **12**, wherein said active agent is encapsulated by the lipid vesicle.

36. (withdrawn): A pharmaceutical composition comprising:
a pharmaceutical excipient; and
a liposomal formulation comprising a lipid vesicle and at least one single chain lipid active agent.

37. (withdrawn): The composition of claim **36**, wherein said excipient comprises an antioxidant, a co-solvent, a preservative, a flavoring agent, vitamin, a thickening agent, a buffer solution, a wetting agent, an emulsifying agent, a suspending agent, a sweetening agent, a flavoring agent, a perfuming agent or mixtures thereof.